Samyadev Datta, MD - Pharmacology of Low dose Naltrexone in Chronic Pain Management (2019 Conference) (LDN, low dose naltrexone)

Samyadev Datta, MD discusses LDN and ultra-low dose naltrexone (ULDN) to treat chronic pain and inflammatory/autoimmune conditions. He presents on the history and pharmacology of naltrexone, forms in which LDN can be prepared. Several case studies on pain are presented

Paul Battle, PA-C - Autoimmune Hepatitis (2019 Conference) (LDN, low dose naltrexone)

Pamela Smith, MD - LDN and Multiple Sclerosis (2019 Conference) (LDN, low dose naltrexone)

Nasha Winters, ND - Quelling the side effects of immune therapies with LDN (2019 Conference) (LDN, low dose naltrexone)

Mark Cooper, PhD - LDN, Endosomes and the Nanophysilogy of Autoimmune Movement Disorders II (2019 Conference) (LDN, low dose naltrexone)

Mark Cooper, PhD - LDN, Endosomes and the Nanophysilogy of Autoimmune Movement Disorders I (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD - LDN should be considered a first-line therapy for CFS/FM (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD - Causes of Hashimoto's (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD discusses Hasimoto’s thyroiditis at the LDN 2019 Conference. He discusses the mechanisms of thyroid dysfunction, causes and evaluation of Hashimoto’s thyroiditis, Hashimoto’s in obesity, and treatments of Hasimoto's
 

Igor Schwartzman, ND - The Art of LDN Prescribing In Hashimoto’s Thyroiditis (2019 Conference) (LDN, low dose naltrexone)

Igor Schwartzman, ND discusses the use of LDN in Hashimoto’s thyroiditis. He presents clinical characteristics, symptoms, and diagnostic criteria; possible causes, forms of thyroiditis, when LDN would benefit, dosing, and when to stop LDN.

Ginevra Liptan, MD - Turning down the volume on fibromyalgia pain (2019 Conference) (LDN, low dose naltrexone)

Ginevra Liptan, MD discusses fibromyalgia, including its symptoms, the CNS sensitization in fibromyalgia, how LDN can lessen fibromyalgia pain, and ways to avoid interactions between opiate-based pain medications and LDN. Case studies.